December 2, 2013
Guideline SummariesNational Institute for Health and Care Excellence (NICE)
- Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer.
- Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer.
- Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion.